Related Experiment Videos
Bleeding in a patient receiving platelet aggregation inhibitors.
J H Waters1, D G Anthony, A Gottlieb
1Department of General Anesthesiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. Watersj@ccf.org
Anesthesia and Analgesia
|September 28, 2001
Summary
This case study details intraoperative bleeding in a patient receiving the platelet receptor glycoprotein IIb/IIIa antagonist eptifibatide. Monitoring with Sonoclot and Thrombelastograph assessed the drug's antiplatelet effects during surgery.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Background:
- Platelet receptor glycoprotein IIb/IIIa antagonists are crucial in managing acute coronary syndromes.
- Eptifibatide is a commonly used glycoprotein IIb/IIIa inhibitor.
- Understanding its perioperative effects is vital for surgical safety.
Observation:
- A patient undergoing surgery experienced significant intraoperative bleeding.
- The patient had recently been treated with eptifibatide.
- Bleeding complications can occur despite therapeutic interventions.
Findings:
- Sonoclot analysis and Thrombelastography were employed to monitor the antiplatelet activity.
- These methods provided real-time assessment of eptifibatide's impact on hemostasis.
- Monitoring confirmed the sustained antiplatelet effect of eptifibatide.
Implications:
- This case highlights potential bleeding risks associated with eptifibatide in surgical settings.
- Perioperative monitoring of antiplatelet effects is essential for managing such complications.
- Further research may refine management strategies for patients on eptifibatide undergoing surgery.